Axon Enterprise (NASDAQ:AXON) Trading Down 10.8% – Should You Sell?

Posted by Stanley Muller on Aug 8th, 2026

Shares of Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) dropped 10.8% during mid-day trading on Thursday . The stock traded as low as $549.40 and last traded at $543.8090. 684,014 shares traded hands during trading, a decline of 36% from the average session volume of 1,065,041 shares. The stock had previously closed at $609.49.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

Positive Sentiment: Strong Q2 growth and higher outlook: Axon reported second-quarter revenue of approximately $904 million, up 35% year over year and above analyst expectations. The company raised its 2026 revenue-growth forecast to 32%–34%, citing record bookings, international expansion and demand for its connected devices and software. Axon Beat Estimates and Raised Guidance, Shares Dropped
Positive Sentiment: AI and Dedrone momentum: AI Era revenue, including Draft One automated police-report software, grew nearly 700% from a year earlier. Dedrone counter-drone revenue exceeded $100 million, supported by deployments at all 11 World Cup sites, strengthening Axon’s long-term growth narrative. Axon Stock Falls After AI, Drone Wins Fuel Q2 Earnings Beat
Positive Sentiment: Analyst and retail support: UBS raised its price target to $600 while maintaining a Neutral rating, and retail traders showed interest in buying the post-earnings pullback. William Blair also reiterated a Buy rating, highlighting recurring-revenue growth, counter-drone demand and Axon’s expanding AI platform. UBS Raises Axon Price Target
Neutral Sentiment: Valuation remains elevated: Axon’s rapid share-price recovery has increased scrutiny of its valuation. Some analysis considers the stock expensive on discounted cash flow and only fairly valued on sales multiples, potentially limiting further gains unless growth remains strong. Axon Stock Could Be Overvalued
Negative Sentiment: Margins and cash flow pressured the initial reaction: Software gross margin declined to 71.3% from 75.6%, while a greater mix of professional services, memory costs and investments in new products reduced profitability. Free cash flow also turned negative, and quarterly EPS was reported as slightly below some consensus estimates, prompting an initial post-earnings selloff. Axon Posts Lower Quarterly Gross Margin

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Morgan Stanley upped their target price on Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a research report on Thursday. The Goldman Sachs Group reissued a “buy” rating and set a $715.00 price target on shares of Axon Enterprise in a research report on Thursday. Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Citizens Jmp reaffirmed a “market outperform” rating and issued a $700.00 price target on shares of Axon Enterprise in a report on Thursday, June 25th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $730.92.

Read Our Latest Report on Axon Enterprise

Axon Enterprise Price Performance

The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The company has a 50 day simple moving average of $513.80 and a 200-day simple moving average of $474.59. The stock has a market cap of $46.02 billion, a price-to-earnings ratio of 236.93, a PEG ratio of 10.66 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.84 by $0.04. The firm had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same period last year, the business posted $2.12 earnings per share. As a group, research analysts anticipate that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $400.00, for a total value of $800,000.00. Following the transaction, the insider directly owned 52,813 shares in the company, valued at approximately $21,125,200. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 58,989 shares of company stock worth $30,527,983. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Evergreen Capital Management LLC boosted its stake in shares of Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Axon Enterprise by 1.2% during the second quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after buying an additional 19 shares during the last quarter. Synergy Financial Group LTD lifted its holdings in Axon Enterprise by 1.4% in the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after buying an additional 19 shares during the period. Certuity LLC lifted its holdings in Axon Enterprise by 5.1% in the fourth quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 23 shares during the period. Finally, Pure Financial Advisors LLC boosted its position in Axon Enterprise by 6.7% during the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 23 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.